At the convergence of nanoscience and molecular biology, our research aims at developing new molecular imaging tracers and to elucidate their behaviour within biological and/or pathological tissues.

Building on the expertise at UniSA in biointerfacial science (Prof Hans Griesser), we have developed a number of approaches and concepts to efficiently target inorganic nanoparticulate contrast agents to tumour or lymphoid cells. Our basic research in this area also aims to take advantage of our “tumour-on-chip” in vitro models to investigate the key physicochemical and biochemical properties that govern the transport, binding and clearance of functional nanomedicine agents inside tumour tissues.

Our specific translational focus is on the development of clinical PET and MRI imaging tracers.

“Next Generation” MRI tracers based on the iron core-shell technology developed by our collaborator Prof Richard Tilley at UNSW are being applied for the imaging of metastatic deposits. Please also refer to Ferronova for more info.

“Chelator-free” PET tracers have the potential to eliminate issues commonly associated with current molecular PET tracers. In collaboration with the South Australian Health and Medical Research Institute, we are developing a new generation of molecular tumour contrast agents.


 Molecular imaging











Leave a Reply